BioDrugs

, Volume 28, Issue 3, pp 237–244 | Cite as

Calcitonin Gene-Related Peptide Targeted Immunotherapy for Migraine: Progress and Challenges in Treating Headache

Leading Article

Abstract

A role for calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine has been established over the past 25 years. There have now been at least five different small-molecule CGRP antagonists that have demonstrated statistical proof of efficacy in the acute treatment of migraine. At present, multiple clinical trials are underway that are assessing the ability of long-acting antibodies against CGRP to prevent frequent migraine attacks. This review summarizes the existing data concerning the role of CGRP in migraine and attempts to highlight some possible outcomes from the ongoing anti-CGRP antibody trials.

References

  1. 1.
    Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20(10):907–18.PubMedCrossRefGoogle Scholar
  7. 7.
    Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet. 1988;1(8598):1309–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Connor KM, Shapiro RE, Diener H-CC, Lucas S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970–7.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–23.PubMedCrossRefGoogle Scholar
  14. 14.
    MK0974 for migraine prophylaxis in patients with episodic migraine. 2013 [ClinicalTrials.gov identifier NCT00797667]. http://clinicaltrials.gov. Accessed 19 Jan 2014.
  15. 15.
    Merck. Merck announces second quarter 2011 financial results. Merck Newsroom, 2011. http://www.mercknewsroom.com/press-release/financial-news/merck-announces-second-quarter-2011-financial-results. Accessed 19 Jan 2014.
  16. 16.
    Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Diener H-C, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–25.Google Scholar
  19. 19.
    Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs. 2012;21(6):807–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393–406.PubMedCrossRefGoogle Scholar
  21. 21.
    deHoon J, Montieth D, Vermeersch S, Van Hecken A, Abu-Raddad E. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP [abstract]. Cephalalgia. 2013;33(8 Suppl):247–248.Google Scholar
  22. 22.
    Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2013.Google Scholar
  23. 23.
    Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang YH, Morita H, et al. Elevated sympathetic nervous activity in mice deficient in CGRP. Circ Res. 2001;89(11):983–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Kurihara H, Kuwaki T. Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. Hypertens Res. 2003;26 Suppl:S105–8.Google Scholar
  25. 25.
    Bowers MC, Katki KA, Rao A, Koehler M, Patel P, Spiekerman A, et al. Role of calcitonin gene-related peptide in hypertension-induced renal damage. Hypertension. 2005;46(1):51–7.Google Scholar
  26. 26.
    Supowit SC, Rao A, Bowers MC, Zhao H, Fink G, Steficek B, et al. Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension. 2005;45(1):109–14.Google Scholar
  27. 27.
    Mishima T, Ito Y, Hosono K, Tamura Y, Uchida Y, Hirata M, et al. Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am J Physiol Heart Circ Physiol. 2011;300(10):H431–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Walker CS, Li X, Whiting L, Glyn-Jones S, Zhang S, Hickey AJ, et al. Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity. Endocrinology. 2010;151(9):4257–69.Google Scholar
  29. 29.
    Kroeger I, Erhardt A, Abt D, Fischer M, Biburger M, Rau T, et al. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol. 2009;51:342–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Kamiyoshi A, Sakurai T, Ichikawa-Shindo Y, Iinuma N, Kawate H, Yoshizawa T, et al. Endogenous alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A. Liver Int. 2009;29:642–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Ohno T, Hattori Y, Komine R, Ae T, Mizuguchi S, Arai K, et al. Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology. 2008;134:215–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Toda M, Suzuki T, Hosono K, Hayashi I, Hashiba S, Onuma Y, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci U S A. 2008;105:13550–5.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Majima M, Mishima T, Toda M, Suzuki T, Ito Y, Ohno T, et al. Roles of calcitonin gene-related peptide in enhancement of angiogenesis. Inflamm Regen. 2011;31:146–50.CrossRefGoogle Scholar
  34. 34.
    Mikami N, Matsushita H, Kato T, Kawasaki R, Sawazaki T, Kishimoto T, et al. Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. J Immunol. 2011;186(12):6886–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Odar-Cederlöf I, Theodorsson E, Eriksson CG, Kjellstrand CM. Plasma concentrations of calcitonin gene-related peptide increase during haemodialysis: relation to blood pressure. J Intern Med. 1989;226:177–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Odar-Cederlöf I, Theodorsson E, Ericsson F, Kjellstrand CM. Plasma concentrations of calcitonin gene-related peptide in fluid overload. Lancet. 1991;338:411–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Wyon Y, Frisk J, Lundeberg T, Theodorsson E, Hammar M. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas. 1998;30:289–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Wyon YA, Spetz AC, Theodorsson GE, Hammar ML. Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. Menopause. 2000;7(1):25–30.Google Scholar
  39. 39.
    Wyon Y, Spetz AC, Hammar M, Theodorsson E, Varenhorst E. Urinary excretion of calcitonin gene-related peptide in males with hot flushes after castration for carcinoma of the prostate. Scand J Urol Nephrol. 2001;35:92–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Onuoha GN, Alpar EK. Calcitonin gene-related peptide and other neuropeptides in the plasma of patients with soft tissue injury. Life Sci. 1999;65:1351–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Takeuchi H, Kawaguchi S, Ohwada O, Kobayashi H, Hayakawa M, Takebayashi T, et al. Plasma neuropeptides in patients undergoing lumbar discectomy. Spine (Phila. Pa. 1976). 2007;32:E79–E84.Google Scholar
  42. 42.
    Onuoha GN, Alpar EK. Elevation of plasma CGRP and SP levels in orthopedic patients with fracture neck of femur. Neuropeptides. 2000;34:116–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Onuoha GN. Circulating sensory peptide levels within 24 h of human bone fracture. Peptides. 2001;22:1107–10.PubMedCrossRefGoogle Scholar
  44. 44.
    Onuoha GN, Alpar EK. Levels of vasodilators (SP, CGRP) and vasoconstrictor (NPY) peptides in early human burns. Eur J Clin Invest. 2001;31:253–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Wiśnicka B, Szepietowski JC, Orda A, Reich A. Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients. Dermatol Psychosom. 2004;5:73–8.CrossRefGoogle Scholar
  46. 46.
    Reich A, Orda A, Wiśnicka B, Szepietowski JC. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol. 2007;16:421–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Reich A, Orda A, Wiśnicka B, Szepietowski JC. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol. 2007;87:299–304.PubMedCrossRefGoogle Scholar
  48. 48.
    Zelissen PM, Koppeschaar HP, Lips CJ, Hackeng WH. Calcitonin gene-related peptide in human obesity. Peptides. 1991;12:861–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: epidemiology, mechanisms, and implications. Headache. 2010;50:631–48.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Evans RW, Williams MA, Rapoport AM, Peterlin BL. The association of obesity with episodic and chronic migraine. Headache. 2012;52(4):663–71.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Bigal M, Rapoport A. Obesity and chronic daily headache. Curr Pain Headache Rep. 2012;16:101–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Peterlin BL, Rosso AL, Williams MA, Rosenberg JR, Haythornthwaite JA, Merikangas KR, et al. Episodic migraine and obesity and the influence of age, race, and sex. Neurology. 2013;81(15):1314–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Juhasz G, Modosa EA, Olajosb S, Jakabc B, Nemeth J, Szolcsanyi J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106(3):461–70.Google Scholar
  54. 54.
    Jang M-U, Park J-W, Kho H-S, Chung S-C, Chung J-W. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral Dis. 2011;17(2):187–93.PubMedCrossRefGoogle Scholar
  55. 55.
    Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Wang Z, Guo J, Wang X, Zhao Y, Hou L. The relationship between serum calcitonin gene-related peptide, sex hormone, homocysteine and coronary artery disease in postmenopausal women. Zhonghua Nei Ke Za Zhi. 2004;43:679–81.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.CarmelUSA

Personalised recommendations